2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Emerging Technologies, Treatment Considerations, Combination Therapy, Drug Development, Drug-Drug Interactions, Supportive Care, Therapy Sequence, Non-Biological Therapies, Chemotherapy, Pharmacology, Adverse Events, Artificial Intelligence (AI), Computer Vision, Generative AI, Machine Learning, Natural Language Processing, Biological Processes, Apoptosis, Genomics, Microbiome, Clinical Practice (Health Services and Quality), Health Economics, Patient Safety, Quality Improvement, Quality of Care, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Measurable Residual Disease, CLL, Non-Hodgkin Lymphoma, B Cell Lymphoma, Aggressive Lymphoma, Research, Translational Research, Clinical Research, Clinical Trials, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly
PAPER

5670 MRD-guided ibrutinib with venetoclax is superior to ibrutinib monotherapy in TP53 aberrated frontline CLL patient: Results of randomised adapted Phase III FLAIR trial

Talha Munir, MBBS, MRCP , PhD, Surita Dalal, PhD2, Sean Girvan3, David Cairns, PhD4, David Allsup5, Abraham Mullasseril Varghese, PhD, FRCPath6, Adrian Bloor7, Claire Hutchinson8, Satyen Gohil, MD, PhD, MRCP, FRCPath9, Renata Walewska, MD10, Francesco Forconi11, Simona Gatto12, Mac Macheta13, Moez Dungarwalla14, Earnest Heartin15, Sasha Marks16, Anthony Todd, PhD17, Sunil Iyengar, PhD18, Andy Rawstron, PhD19, Nichola Webster20, Charlotte Louise Evans, PhD21, Sharon Jackson22, Natasha Greatorex23, Sue Bell24, David Stones25, Julia Brown26, Hilary Lindsay27, Debbie Yates28, Piers E M Patten, MB ChB PhD29, Peter Hillmen, PhD, MBBCh30
1 Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom
2 Haematological Malignancy Diagnostic Service, Leeds, United Kingdom, Leeds Institute of Medical Research, Leeds, United Kingdom
3 Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, United Kingdom
4 Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, United Kingdom
5 Hull University Teaching Hospitals NHS Trust, Hull, United Kingdom
6 Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom
7 The Christie Hospital NHS Foundation Trust, Manchester, United Kingdom, University of Manchester, Manchester, United Kingdom
8 University Hospitals Plymouth NHS Trust, Plymouth, United Kingdom, University of Plymouth, Plymouth, United Kingdom
9 University College London Hospitals NHS Foundation Trust, London, United Kingdom
10 University Hospitals Dorset NHS Foundation Trust, Bournemouth, United Kingdom
11 University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom, University of Southampton, Southampton, United Kingdom
12 University Hospital of Wales, Cardiff, United Kingdom
13 Blackpool Teaching Hospitals NHS Foundation Trust, Blackpool, United Kingdom
14 Milton Keynes University Hospital NHS Foundation Trust, Milton Keynes, United Kingdom
15 Glan Clwyd Hospital, Rhyl, United Kingdom
16 Hammersmith Hospital, London, United Kingdom
17 Royal Devon and Exeter Hospital, Exeter, United Kingdom
18 Royal Marsden Hospital, London, United Kingdom
19 Haematological Malignancy Diagnostic Service, Leeds, United Kingdom
20 Haematological Malignancy Diagnostic Service, Leeds, United Kingdom, Leeds Institute of Medical Research, Leeds, United Kingdom
21 Haematological Malignancy Diagnostic Service, Leeds, United Kingdom, Leeds Institute of Medical Research, Leeds, United Kingdom
22 Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, United Kingdom
23 Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, United Kingdom
24 Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, United Kingdom
25 Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, United Kingdom
26 Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, United Kingdom
27 CLL Support, Chippenham, United Kingdom
28 CLL Support, Chippenham, United Kingdom
29 Comprehensive Cancer Centre, London, United Kingdom, King’s College Hospital NHS Foundation Trust, London, United Kingdom
30 Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom

Introduction
The FLAIR (ISRCTN01844152) phase III trial for previously untreated fit CLL patients showed that measurable residual disease (MRD)-guided ibrutinib-venetoclax (I+V) significantly improved response, progression-free survival (PFS), and overall survival (OS) compared to ibrutinib-alone (IBR) or fludarabine-cyclophosphamide-rituximab (FCR). FLAIR initially excluded patients with TP53 deletion >20% detected by FISH. A high-risk cohort of TP53 deleted patients was added and randomised between IBR or MRD-guided I+V. MRD-guided end-of treatment (MRD-EoT) occurred at twice the time taken to achieve confirmed uMRD4 (defined as first PB uMRD4 sustained for six months confirmed with BM uMRD4), minimum 2 years (yrs) maximum 6yrs of treatment. MRD relapse was defined as >0.01% disease in PB. 

Initial plans were to randomise 66 patients, but recruitment was stopped after 21 patients due to changing landscape of CLL treatment and slow recruitment. However, in the standard-risk arm of FLAIR, 70 patients without TP53 deletion were found to have TP53 mutations when analysed retrospectively. This analysis reports the primary endpoint of achievement of uMRD4 at 2 years of completion for the randomised cohort and additional analysis for the 91 patients in the combined TP53 deleted and mutated cohorts.

Methods
Participants were randomly assigned (1:1) to MRD-guided IBR or I+V. The primary endpoint for I+V vs. IBR was undetectable MRD (uMRD) in the bone marrow (BM) within 2 years. Other secondary endpoints included progression-free survival (PFS), overall survival (OS), pattern of MRD relapse and retreatment in IBR-containing therapy, health-related quality of life, and cost-effectiveness. Additional analysis strategy was developed which combined participants randomised to the genetically high-risk (GHR) with participants randomised to FCR, I containing arm (IBR and IBR-rituximab) and I+V in the standard risk pathway who were found to have >20% of chromosome 17p deleted or TP53 mutations post-randomisation as these standard risk participants received the same treatment as participants in the high-risk pathway.

Results
In the randomised cohort, 11 and 10 participants were randomised to receive IBR or MRD-guided I+V. For the combined GHR analysis, 28, 42 and 21 participants were randomised to receive FCR, I-containing arms and MRD-guided I+V, respectively. In the I+V arm, 13/7/4/0 received 2, 3, 4 and 6 years of MRD-guided I+V.

For the primary endpoint analysis for the randomised cohort, uMRD in bone marrow (BM) was achieved in 6/10 participants in the MRD-guided I+V group as compared to 0/11 participant in the IBR arm. The odds ratio (OR) of becoming MRD-negative in the bone marrow within 2 years post-randomisation was 22.99 (95% CI: [1.37, 386.50], p=0.0295) and OR of 10.33 (95% CI: [1.25, 85.14], p= 0.0301) in peripheral blood with I+V as compared to IBR.

In the combined GHR analysis for TP53 disrupted patients, MRD-guided I+V resulted in superior PFS compared with combined ibrutinib arms and FCR. Median PFS was 60.0 and 72.6 months for FCR and I-containing arms, whereas no progressions have been reported for MRD-guided I+V with a median follow up of 59 months. The results were statistically significant in favour of MRD-guided I+V versus I-containing arms (P=0.003) and FCR (P=<0.0001). Median PFS for IGHV-unmutated (UM) TP53 aberrated participants in FCR, I-containing arms and I+V arms were 32.9, 67.9 months and not reached, respectively. For IGHV-mutated TP53 aberrated participants, the median PFS was not reached in the I+V arm but was 69.9 and 95.6 months in FCR and I-containing arms, respectively. The OS estimates at 6 years for FCR, I-containing arms and I+V were 83.6, 86.2 and 100%, respectively. MRD relapse happened in 2 IGHV-UM participants in the I+V GHR group.

Conclusions
In the genetically high-risk group defined by TP53-aberration, MRD-guided I+V resulted in deeper MRD remissions than the ibrutinib-only arm. MRD-guided I+V resulted in superior PFS and OS compared to ibrutinib-containing arms and FCR. These randomised results further establish the role of MRD-guided I+V as standard of therapy for genetically high-risk CLL.

Talha Munir, MBBS, MRCP , PhD: Alexion Pharmaceuticals - Other (including travel support); Janssen-Cilag - Other (including travel support); SOBI - Honoraria; Janssen-Cilag - Honoraria; Nurix - Honoraria; AstraZeneca - Honoraria; Johnson & Johnson - Honoraria; AbbVie - Honoraria; Roche - Honoraria; BeOne - Honoraria; Alexion Pharmaceuticals - Honoraria; Novartis - Honoraria; Janssen-Cilag - Research Funding; AbbVie - Research Funding; Johnson & Johnson - Research Funding; BeOne - Consultancy (Includes expert testimony); SOBI - Consultancy (Includes expert testimony); Alexion Pharmaceuticals - Consultancy (Includes expert testimony); AbbVie - Consultancy (Includes expert testimony); Roche - Consultancy (Includes expert testimony); Lilly - Consultancy (Includes expert testimony); AstraZeneca - Consultancy (Includes expert testimony); Janssen-Cilag - Consultancy (Includes expert testimony)